Antiretroviral drug interactions

1995 ◽  
Vol 5 (2) ◽  
pp. 73-83 ◽  
Author(s):  
Edward P. Acosta ◽  
Courtney V. Fletcher
Keyword(s):  
Drug Interactions ◽  
Antiretroviral Drug

scholarly journals Emerging antiretroviral drug interactions

2010 ◽  
Vol 66 (2) ◽  
pp. 235-239 ◽  
Author(s):  
P. A. Pham ◽  
C. Flexner
Keyword(s):  
Drug Interactions ◽  
Antiretroviral Drug

Antiretroviral drug interactions

2005 ◽  
pp. 305-318
Author(s):  
Thomas N. Kakuda ◽  
Courtney V. Fletcher
Keyword(s):  
Drug Interactions ◽  
Antiretroviral Drug

scholarly journals Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable

2009 ◽  
Vol 64 (1) ◽  
pp. 5-8 ◽  
Author(s):  
K. Seden ◽  
D. Back ◽  
S. Khoo
Keyword(s):  
Drug Interactions ◽  
Antiretroviral Drug

scholarly journals Outcomes of Dosage Adjustments Used to Manage Antiretroviral Drug Interactions

2007 ◽  
Vol 45 (7) ◽  
pp. 933-936 ◽  
Author(s):  
L. Y. Park-Wyllie ◽  
M. A. Levine ◽  
A. Holbrook ◽  
L. Thabane ◽  
T. Antoniou ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Antiretroviral Drug

scholarly journals Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention

2020 ◽  
Author(s):  
A T Podany ◽  
J Leon-Cruz ◽  
J Hakim ◽  
K Supparatpinyo ◽  
A Omoz-Oarhe ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Drug Interactions ◽  
Geometric Mean ◽  
People Living With Hiv ◽  
Oral Clearance ◽  
Geometric Mean Ratio ◽  
Antiretroviral Drug ◽  
Trough Concentrations ◽  
Study Participants ◽  
Living With Hiv

Abstract Background The use of rifamycin antibiotics for TB prevention carries a risk of detrimental drug–drug interactions with concomitantly used ART. Objectives To evaluate the interaction of the antiretroviral drug nevirapine in combination with 4 weeks of daily rifapentine and isoniazid for TB prevention in people living with HIV. Methods Participants were individuals enrolled in the BRIEF-TB study receiving nevirapine and randomized to the rifapentine/isoniazid arm of the study. Participants provided sparse pharmacokinetic (PK) sampling at baseline and weeks 2 and 4 for trough nevirapine determination. Nevirapine apparent oral clearance (CL/F) was estimated and the geometric mean ratio (GMR) of CL/F prior to and during rifapentine/isoniazid was calculated. Results Seventy-eight participants had evaluable PK data: 61 (78%) female, 51 (65%) black non-Hispanic and median (range) age of 40 (13–66) years. Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266–9302) ng/mL; week 2, 5537 (3552–8462) ng/mL; and week 4, 5388 (3516–8243) ng/mL. Sixty out of 78 participants (77%) had nevirapine concentrations ≥3000 ng/mL at both week 2 and 4. Median (IQR) nevirapine CL/F values were: week 0 pre-rifapentine/isoniazid, 2.03 (1.58–2.58) L/h; and during rifapentine/isoniazid, 2.62 (1.81–3.42) L/h. The GMR (90% CI) for nevirapine CL/F was 1.30 (1.26–1.33). Conclusions The CL/F of nevirapine significantly increased with concomitant rifapentine/isoniazid. The decrease in nevirapine trough concentrations during rifapentine/isoniazid therapy suggests induction of nevirapine metabolism, consistent with known rifapentine effects. The magnitude of this drug–drug interaction suggests daily rifapentine/isoniazid for TB prevention should not be co-administered with nevirapine-containing ART.

scholarly journals Drug Interactions and Antiretroviral Drug Monitoring

2014 ◽  
Vol 11 (3) ◽  
pp. 212-222 ◽  
Author(s):  
Matthew Foy ◽  
C. John Sperati ◽  
Gregory M. Lucas ◽  
Michelle M. Estrella
Keyword(s):  
Drug Interactions ◽  
Drug Monitoring ◽  
Antiretroviral Drug
Sign in / Sign up

Export Citation Format

Share Document